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to recurrence of hepatitis C virus infection or other underly-
ing liver diseases after transplantation. TE cannot complete-
ly replace other tests accompanied with hepatic surgical 
treatments, including LB, endoscopic examination, hepatic 
venous pressure gradient evaluation, or the indocyanine 
green retention test. However, TE represents an important 
non-invasive tool that enables more efficient and tailored 
management strategies for patients who were treated with 
liver resection or transplantation. This review discusses ex-
tended TE applications in the surgical setting, such as he-
patic resection or transplantation.  © 2013 S. Karger AG, Basel
 Introduction
 The prognosis and management of chronic liver dis-
ease (CLD) depend mainly on the amount and progres-
sion of liver fibrosis, which results from chronic liver in-
sults  [1, 2] . Thus, accurate determination of the presence 
and degree of liver fibrosis is of paramount importance in 
choosing treatment strategies, evaluating responses to 
treatment, assessing the risk of developing liver-related 
complications, and predicting prognosis in CLD patients. 
As a surrogate for liver biopsy (LB), which is an invasive 
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 Abstract
 Liver biopsy (LB) remains the gold standard for assessing the 
severity of liver fibrosis; however, LB is often limited by its 
invasiveness, sampling error, and intra-/inter-observer vari-
ability in histological interpretation. Furthermore, repeated 
LB examinations within a short time interval are ineligible in 
real clinical practice. Thus, due to the pressing need for non-
invasive surrogates, over the past decade, significant prog-
ress has been made in non-invasively assessing liver fibrosis. 
Of the methods now available, transient elastography (TE) 
appears to be an excellent tool for assessing liver fibrosis and 
also has some prognostic value in surgical settings. Recent 
studies have proposed the extended role of TE in the surgical 
field, based on the concept that TE values show significant 
correlations with portal hypertension and hepatocellular 
carcinoma development. TE appears promising in predicting 
postoperative short-term outcomes such as hepatic insuffi-
ciency or complications and long-term outcomes such as re-
currence or liver-related death. Furthermore, TE may be use-
ful in predicting the severity of liver fibrosis progression due 
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procedure and is often subject to not only sampling error 
but also intra- and inter-observer variability in histologi-
cal interpretation  [3–7] , liver stiffness (LS) measurement 
using transient elastography (TE) was introduced as a 
promising non-invasive method for assessing liver fibro-
sis  [8–13] . In many studies, TE proved reliable and accu-
rate in terms of predicting significant fibrosis or cirrhosis 
 [14–19] . More recently, investigators have identified ad-
ditional important roles for TE, namely predicting long-
term disease prognosis and monitoring clinical courses in 
a longitudinal perspective  [20] . These data indicate that 
TE’s role is not merely limited to lessening the frequency 
of unnecessary LB, but that TE can facilitate establishing 
tailored CLD management strategies by providing more 
detailed prognostic information.
 Interestingly, recent several pilot studies have pro-
posed an extended role for TE in the surgical field, based 
on the concept that TE values show significant correla-
tions with portal hypertension and hepatocellular carci-
noma (HCC) development  [21–24] . Of these, Cescon et 
al.  [22] and Wong et al.  [24] tested the predictive perfor-
mance of TE for postoperative hepatic insufficiency and 
failure after hepatic resection. Additionally, several 
studies proved that TE is useful in predicting the sever-
ity of liver fibrosis progression due to recurrent hepatitis 
C virus (HCV) infection after transplantation  [25–28] . 
If future studies validate the usefulness of TE values in 
the surgical field, TE will rapidly facilitate the risk strat-
ification of patients undergoing surgical management 
according to different prognoses assessed by this ap-
proach.
 In this article, we review recent studies that focus on 
the prognostic value of TE in predicting clinical end-
points after liver resection, from a surgical standpoint. 
These endpoints include not only postoperative hepatic 
insufficiency or complications, but also HCC recurrence 
and liver fibrosis progression after transplantation.
 Prediction of Short- and Long-Term Outcomes Using 
TE after Hepatic Resection
 Postoperative Hepatic Insufficiency and Failure
 With considerable improvements in perioperative in-
tensive care and refined surgical techniques, the rates of 
death and complications after major liver resection sur-
gery have decreased significantly  [29–32] . Nevertheless, 
because many patients still have liver cirrhosis or other 
CLDs, death and complications may follow liver resec-
tion surgery occasionally. Therefore, it is important to in-
vestigate the functional liver reserve before hepatic resec-
tion. To date, some hepatologists favor assessment of he-
patic venous pressure gradient as a preoperative test to 
estimate the portal pressure and liver reserve; however, it 
is not widely accepted owing to its invasiveness. Instead, 
in Eastern countries including Korea and Japan, indocya-
nine green retention rate at 15 min (ICG R15) has been 
widely used. Recently, several studies investigated wheth-
er TE can assess the hepatic functional reserve and if it can 
be used as a predictor of short-term surgical outcomes 
after hepatic resection.
 The first study that extended the scope of TE use to the 
surgical field investigated whether preoperative TE values 
could predict the development of postoperative hepatic 
insufficiency after curative resection of HCC  [21] . In this 
study, postoperative hepatic insufficiency was defined 
as persistent hyperbilirubinemia (total bilirubin level 
 ≥ 5 mg/dl) for more than 5 days after surgery, or postop-
erative death without other identifiable causes. Multivar-
iate analysis revealed that TE values >25.6 kPa were iden-
tified as the only predictor of postoperative insufficiency. 
The area under the receiver operating characteristic curve 
(AUROC) of LS values using TE was higher than that of 
ICG R15 measurements (0.824 vs. 0.620, respectively). 
The usefulness of TE in assessing postoperative hepatic 
insufficiency was also demonstrated in subsequent inves-
tigations  [33] that compared the predictive ability of TE 
with another radiological tool, diffusion-weighted mag-
netic resonance imaging (DW-MRI), using apparent dif-
fusion coefficient values  [34, 35] . In patients who under-
went liver resection for HBV-related HCC, the predictive 
performance of TE was superior to that of DW-MRI (AU-
ROC 0.942 vs. 0.797, respectively). The TE cutoff value 
was set at 22.4 kPa and was similar to that used in a previ-
ous study (25.6 kPa)  [21] . However, these two pilot stud-
ies had several common drawbacks. First, they did not 
consider other variables such as serum hyaluronic acid 
level, which is closely correlated with the functional liver 
reserve and is a useful predictor of liver regeneration  [29] , 
or the concept of ‘future liver remnant volume’ calculated 
using preoperative helical computed tomography scans. 
Second, since the primary endpoint of ‘postoperative he-
patic insufficiency’ in these two studies was defined based 
only on postoperative total bilirubin levels, further stud-
ies using more comprehensive endpoints that cover mild-
er degrees of postoperative hepatic dysfunction should be 
conducted.
 Based on a similar hypothesis by Kim et al.  [21, 33] , a 
more recent study from Hong Kong  [24] also proposed 
the superior performance of TE to that of the ICG R15 in 
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predicting major postoperative complications, defined as 
 ≥ grade 3 complications based on a modified Clavien clas-
sification  [36, 37] . The AUROC of TE and ICG R15 in 
predicting major postoperative complication was 0.79 
and 0.51, respectively, and only TE showed a significant 
positive correlation to the primary endpoint. When the 
optimal cutoff TE value of 12.0 kPa was used, TE dis-
played a hazard ratio of 7.33. Interestingly, operative 
blood loss and blood transfusion rates were significantly 
higher in patients with preoperative TE value  ≥ 12.0 kPa, 
consistent with previous studies that observed greater 
blood loss in cirrhotic patients  [38, 39] . Similar results 
were reported in another recent study  [40] , wherein even 
patients without overt hemostatic disorder at preopera-
tive evaluation were also subject to bleeding risk ac-
cording to the TE values. Whether this higher bleeding 
tendency in cirrhotic patients depends on physical prop-
erties such as technical difficulties during surgical 
manipulation, or functional properties such as a hemo-
static disorder, remains to be determined.
 An Italian study which recruited mostly HCV-related 
HCC also investigated whether preoperative TE can pre-
dict the outcome of hepatic resection for HCC  [22] . In 
this study, the primary endpoint was postoperative liver 
failure (PLF), which was defined more comprehensively 
to cover milder grades of PLF and included the presence 
of at least one of the following variables graded according 
to the Dindo-Clavien classification: occurrence of refrac-
tory ascites, increased bilirubin levels to >3 mg/dl, altered 
coagulation factors requiring fresh frozen plasma infu-
sion, or renal impairment  [37] . ROC analysis identified 
patients with LS values  ≥ 15.7 kPa as being at higher risk 
of PLF (AUROC = 0.865). Multivariate analysis showed 
that low preoperative serum sodium levels, histological 
cirrhosis, and elevated LS values were independent pre-
dictors of PLF  [22] . The authors concluded that LS mea-
surement using TE is a valid tool for predicting PLF in 
patients undergoing hepatectomy for HCC. However, 
ICG R15 data was missing for direct comparison between 
TE and ICG R15.
 Taken together, these two studies confirmed a poten-
tial clinical role for TE as a non-invasive and convenient 
tool for risk stratification or risk disclosure to patients 
before hepatectomy. Future studies based on various 
non-invasive preoperative tools to assess reserve liver 
function including computed tomography volumetry, 
and serological methods such as FibroTest ®  (BioPre-
dictive, Paris, France) and the European Fibrosis Panel 
test, should be compared for their risk stratification 
utility.
 Predicting HCC Recurrence after Hepatic Resection
 Another issue is using preoperative TE to predict HCC 
recurrence after curative resection, i.e. de novo recurrence 
in the background liver with fibrotic burden. In an analysis 
of 133 patients who underwent preoperative TE and cura-
tive resection, HCC recurred in 62 patients  [23] . TE was 
identified as an independent predictor of HCC recurrence, 
whereas histological fibrosis status was not predictive. This 
phenomenon can be explained in several ways  [23] . First, 
because high-risk patients with advanced liver cirrhosis 
where another treatment option such as liver transplanta-
tion is generally prepared were excluded as resection can-
didates, the influence of liver fibrosis on postoperative re-
currence may have been underestimated. Second, patho-
logical factors other than liver fibrosis, which greatly 
contributed to recurrence, may have attenuated the poten-
tial influence of liver fibrosis on recurrence. Third, the 
influence of liver fibrosis also may have been confounded, 
because liver cirrhosis was analyzed as a single category 
without considering the wide-range severity of liver cirrho-
sis. In that study, patients with preoperative TE values >13.4 
kPa were at greater risk for HCC recurrence, with a hazard 
ratio of 1.925 (p = 0.010). When HCC recurrence was strat-
ified into early (<2 years) and late ( ≥ 2 years) recurrence, TE 
values were significantly related to late recurrence. These 
results suggest that preoperative TE could reveal the poten-
tial influence of liver fibrosis on HCC recurrence and ex-
plain multicentric carcinogenesis in the fibrotic liver. How-
ever, more data are needed to clarify this issue.
 Using TE to Predict Short- and Long-Term Outcomes 
after Orthotopic Liver Transplantation
 Monitoring of Graft Function and Complications in 
the Peritransplantation Period
 To date, there has been little evidence that supports TE 
usefulness in monitoring liver grafts in the peritransplan-
tation period. However, some studies indicated that TE 
values in patients with acute liver damage may increase 
substantially regardless of chronic structural changes  [41, 
42] . Thus, TE is hypothesized to be a non-invasive moni-
toring tool to trace dynamic LS changes in post-trans-
plant liver graft. Inoue et al.  [43] measured 678 TE results 
from 24 living donor orthotopic liver transplantation 
(OLT) recipients in the peritransplantation period. They 
reported that TE values were greatest in the first postop-
erative week (mean 24.8 kPa) and declined thereafter. 
Furthermore, recipients who had experienced complica-
tions such as acute cellular rejection, hepatic arterial 
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thrombosis, and sepsis had significantly higher TE values 
than those without complications beyond the fourth (p = 
0.0066) and fifth postoperative week (p = 0.003). Recent-
ly, Lee et al.  [44] reported that greater TE values are as-
sociated with lower graft-to-recipient weight ratios and 
higher serum bilirubin levels in the first week after liver 
transplantation. These phenomena are most likely due to 
persistent hypercirculation and regeneration after trans-
plant, the latter of which is more dynamic during the first 
week after living donor OLT.
 Predicting Graft Disease in Liver Recipients after 
Orthotopic Liver Transplantation
 For patients who underwent OLT, LB has been shown 
to be an important diagnostic and prognostic tool for 
managing recipients. This is because studies of long-term 
OLT patients have shown a high prevalence of histological 
abnormalities in protocol LBs even in the absence of ab-
normal liver function tests  [45–47] . In most OLT patients, 
several risk factors are presumably involved in allograft 
fibrosis progression  [48–50] . For example, in HCV pa-
tients, viral re-infection is likely to be the major factor 
contributing to hepatocyte injury. Fibrosis progression in 
non-HCV patients was attributed to risk factors such as 
metabolic syndrome, non-alcoholic steatohepatitis, and 
history of biliary obstruction, as well as to surgical factors. 
Additionally, profibrogenic effects of calcineurin inhibi-
tors have been demonstrated both in vitro and in vivo, and 
may have contributed to fibrosis progression  [51, 52] . 
Many transplant centers perform protocol LBs to assess 
fibrosis progression to determine the need for specific in-
tervention and for accurate prognostication. However, 
because LB has several inherent drawbacks owing to its 
invasiveness, especially when repeated examinations are 
required, TE might be a good alternative.
 The clinical utility of TE has been investigated to assess 
the severity of recurrent HCV infection  [25, 26, 53, 54] . 
HCV recurrence in post-OLT patients is nearly universal 
and has an unpredictable and often accelerated course of 
disease progression to portal hypertension and liver fail-
ure, versus HCV infection of a native liver  [55, 56] . This 
might explain the more rapid liver fibrosis progression in 
HCV patients when compared with patients transplanted 
for other indications. Hepatitis and fibrosis occur in 75–
80 and 10–30% of recipients, respectively, at 5 years  [57, 
58] . Furthermore, cholestatic hepatitis occurs in approx-
imately 10% of OLT patients and leads to graft failure and 
death  [59] . The presence of significant liver fibrosis at 1 
year after transplantation identifies patients at high risk 
of graft loss  [60, 61] . However, antiviral therapy initiated 
too early has no mortality benefit but often substantial 
side effects, whereas therapy initiated too late may de-
crease efficacy and clinical benefits  [62, 63] . Therefore, 
determining the appropriate timing for commencing an-
tiviral therapy is very important. In this respect  [25–28] , 
TE results are well correlated with liver fibrosis histolog-
ical scores, although some influence of hepatitis-associat-
ed necroinflammatory activity is observed. The study by 
Carrión et al.  [26] reported that the AUROC was 0.90 for 
significant fibrosis and 0.98 for cirrhosis in 124 liver 
transplant recipients with recurrent HCV infection. Us-
ing a cutoff value of 8.5 kPa, the sensitivity, specificity, 
negative predictive value, and positive predictive value of 
TE for diagnosing significant liver fibrosis were 90, 81, 79, 
and 92%, respectively. When using a cutoff value of 12.5 
kPa, the sensitivity, specificity, negative predictive value, 
and positive predictive value for cirrhosis diagnosis were 
100, 87, 50, and 100%, respectively. These findings were 
supported by subsequent studies  [27, 28] . In a prospec-
tive, longitudinal study of sequential paired examinations 
using TE and LB in liver graft recipients with recurrent 
HCV, TE changes over time were dynamically correlated 
not only with changes in liver fibrosis stage but also with 
changes in necroinflammatory activity and the occur-
rence of complications such as cellular rejection, cho-
lestasis, and de novo autoimmune hepatitis  [25] .
 These observations indicate that TE is a reliable pre-
dictor of liver graft damage independent of HCV recur-
rence. However, there remain only limited data about the 
clinical application of TE in patients undergoing trans-
plantation for end-stage liver diseases other than HCV. 
Beckebaum et al.  [64] prospectively assessed the efficacy 
of TE, biochemical tests, and more complex scores in de-
termining fibrosis stage in 157 patients transplanted for 
HCV infection or non-HCV-related liver diseases. Al-
though TE performed better in HCV patients than in 
non-HCV patients, it is still a reliable method of assessing 
severe fibrosis in HCV patients: the optimal TE cutoff 
values were 4.7 and 5.0 kPa for F  ≥ 1, 7.1 and 7.3 kPa for 
F  ≥ 2, 10.9 and 9.9 kPa for F  ≥ 3, and 17.3 and 12.6 kPa 
for F = 4, respectively, in HCV versus non-HCV patients. 
The corresponding AUROCs for F  ≥ 1, F  ≥ 2, F  ≥ 3, and 
F = 4 were 0.95 and 0.86, 0.89 and 0.85, 0.97 and 0.88, and 
0.99 and 0.97, respectively, for HCV versus non-HCV pa-
tients. In another prospective study by Rigamonti et al. 
 [65] , TE proved to be an accurate and independent pre-
dictor of graft damage regardless of the etiology, which 
was not an unexpected finding because TE-measured LS 
was previously shown to correlate not only with liver 
fibrosis but also with necroinflammatory activity, cho-
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lestasis, steatosis, and cellular rejection. They identified 
two TE cutoffs for diagnosing graft damage: 5.3 kPa with 
100% sensitivity and 7.4 kPa with 100% specificity. In pa-
tients with TE values  ≤ 5.3 kPa, the post-test probability 
of graft damage fell to 0%, but in patients with TE results 
>7.4 kPa, the post-test probability increased to 100%  [65] .
 Because histological changes are potentially clinically 
significant (e.g. progressive graft fibrosis), monitoring 
patients with TE to identify the presence of graft damage 
may be valuable for early identification of OLT patients 
that require further histological assessment of the graft or 
modifications of their immunosuppressive therapy regi-
men  [66, 67] .
 Limitations of TE and Future Perspectives
 Although TE has demonstrated reliable diagnostic ac-
curacy in the surgical setting, it still has a limitation in that 
space-occupying tissue abnormalities such as edema, in-
flammation, cholestasis, and congestion after surgery may 
interfere with TE utility regardless of the liver fibrosis de-
gree. First, the extent of histological necroinflammatory 
activity influences TE results, resulting in an overestima-
tion of TE values that increases in parallel with the degree 
of necroinflammatory score  [29, 41, 42, 68–74] . Since even 
mild to moderate ALT elevation is associated with higher 
LS values, and may cause discrepancies between TE results 
and the actual underlying fibrosis, physicians should ex-
ercise caution in interpreting TE results. Apart from 
necroinflammation, underlying extrahepatic cholestasis 
 [75] may also contribute to overestimating TE. Because 
the temporary increase of portal blood flow immediately 
after hepatic resection can lead to postoperative liver con-
gestion, the optimal timing for acquiring the stabilized LS 
values should be further investigated. Second, TE perfor-
mance may be limited in patients with a high body mass 
index or narrow intercostal space  [8] . Although TE repro-
ducibility is typically excellent in terms of inter- and intra-
observer agreement, a high body mass index (>28) and 
waist circumference are significantly associated with TE 
failure  [76] . These results emphasize the need for adequate 
operator training and for technological improvements in 
specific patient populations, such as those with non-alco-
holic fatty liver disease. A new TE probe (the XL probe) 
was recently introduced to lessen the TE failure rate in 
obese patients; however, its efficacy requires further vali-
dation  [77] . Lastly, if patients undergo right hepatectomy, 
measurement of LS by TE of the right lobe will be no lon-
ger possible, and obtaining LS values for the remnant left 
lobe has not yet been standardized. In such cases, other 
imaging modalities covering the left lobe such as MR elas-
tography or acoustic radiation force impulse imaging 
would be potential alternatives. However, their diagnostic 
performance requires validation in future studies.
 Although there are several kinds of non-invasive elas-
tography modalities in addition to TE, including acous-
tic-radiation-force impulse elastography (ARFI), real-
time elastography, and spleen stiffness index, their uses in 
a surgical field are not widely accepted. Hence, we could 
not incorporate their predictive performances in this re-
view. Considering that these elastography methods had 
similar diagnostic performances to predict liver cirrhosis 
 [78–81] and that spleen stiffness had showed the promis-
ing results to assess the portal hypertension from more 
recent investigations  [82–84] , further studies are required 
to find whether they have the better predictive perfor-
mances to predict postoperative outcomes.
 Furthermore, in contrast to TE and other elastography 
methods, ARFI is the only elastography method suitable 
for quantifying the stiffness of focal liver mass, since it 
uses elastography with a flexible metering box of the re-
gion of the interest. Park et al.  [85] and other investigators 
 [86] reported the usefulness of characterization of focal 
liver masses based on ARFI method, suggesting the high-
er likelihood of malignancy when the ARFI velocity is 
>1.82–1.9 m/s. However, these results should be inter-
preted in a clinical context, because considerable overlap 
in ARFI values existed among liver masses. Additional 
roles of ARFI in the surgical perspectives should be inves-
tigated in future studies.
 Conclusion
 Over the past decade, significant progress has oc-
curred in the non-invasive assessment of liver fibrosis in 
patients with CLD. Of the methods now available, TE 
appears to be an excellent tool for assessing liver fibrosis, 
particularly for diagnosing cirrhosis, and it also has good 
prognostic value in the surgical setting. Although TE 
cannot completely obviate the other tests, such as LB, en-
doscopic examination, hepatic venous pressure gradient, 
or ICG R15, it represents an important non-invasive tool 
which enables more efficient and tailored management 
strategies for patients with liver resection or transplanta-
tion.
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